Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has issued an announcement.
Sihuan Pharmaceutical Holdings Group has issued a profit warning, expecting significant financial challenges for the year ending December 2024. The company anticipates a revenue of at least RMB1,800 million but a loss of up to RMB600 million, mainly affected by declining generic drug sales due to PRC’s centralized procurement policy and high R&D costs for innovative drugs. However, the company has received approvals for new drugs, including biosimilars and generics, and expects its medical aesthetics business to continue growing, potentially boosting future revenue and profits.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group is a healthcare company primarily involved in the production of generic drugs, medical aesthetics, and innovative drug research and development. The company is focused on the Chinese market, where its drug development and manufacturing operations are subject to regulatory policies like centralized procurement.
YTD Price Performance: 67.35%
Average Trading Volume: 165
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $706.2M
For detailed information about 0460 stock, go to TipRanks’ Stock Analysis page.